Free Trial
NASDAQ:ELTX

Elicio Therapeutics Q1 2024 Earnings Report

Elicio Therapeutics EPS Results

Actual EPS
-$1.15
Consensus EPS
-$1.09
Beat/Miss
Missed by -$0.06
One Year Ago EPS
N/A

Elicio Therapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Elicio Therapeutics Announcement Details

Quarter
Q1 2024
Time
N/A
Conference Call Date
Tuesday, May 14, 2024
Conference Call Time
6:00PM ET

Earnings Documents

Elicio Therapeutics Earnings Headlines

Elicio Therapeutics Reports Inducement Grants
Make this AI Trade Before EOM
President Trump is set to sign a game-changing new law… That I believe will trigger a boom in a handful of artificial intelligence coins… Giving you a chance to turn a small stake into a six-figure payout.tc pixel
See More Elicio Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Elicio Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Elicio Therapeutics and other key companies, straight to your email.

About Elicio Therapeutics

Angion Biomedica Corp. is a late-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of novel small molecule therapeutics to address acute organ injuries and fibrotic diseases. Angion Biomedica Corp. is based in UNIONDALE, N.Y.

View Elicio Therapeutics Profile

More Earnings Resources from MarketBeat